Skip to main content
letter
. 2021 Dec 7;10(24):e023143. doi: 10.1161/JAHA.121.023143

Figure 1. Efficacy and safety end points stratified by a history of heart failure, use of apixaban vs vitamin K antagonist, and aspirin vs placebo.

Figure 1

A, Apixaban vs vitamin K antagonist (VKA). B, Aspirin vs placebo. CRNM indicates clinically relevant nonmajor bleeding; ISTH, International Society for Thrombosis and Hemostasis; and KM, Kaplan‐Meier.